Narumi Nakagiri
Stock Analyst at Daiwa
(2.58)
# 2,860
Out of 4,352 analysts
27
Total ratings
64.3%
Success rate
5.2%
Average return
Main Sectors:
Stocks Rated by Narumi Nakagiri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Upgraded: Buy | $94 → $155 | $162.96 | -4.88% | 3 | May 14, 2026 | |
| ABT Abbott Laboratories | Downgraded: Hold | $92 | $85.60 | +7.48% | 1 | Apr 21, 2026 | |
| PFE Pfizer | Downgraded: Hold | $34 → $27 | $26.18 | +3.13% | 4 | Feb 12, 2026 | |
| LLY Eli Lilly and Company | Upgraded: Buy | $700 → $1,230 | $1,105.00 | +11.31% | 3 | Dec 16, 2025 | |
| GILD Gilead Sciences | Upgraded: Buy | $128 | $134.43 | -4.78% | 1 | Aug 18, 2025 | |
| ABBV AbbVie | Upgraded: Buy | $180 → $214 | $217.72 | -1.71% | 3 | Aug 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgraded: Hold | $65 → $42 | $57.18 | -26.55% | 3 | Aug 5, 2025 | |
| EW Edwards Lifesciences | Upgraded: Buy | $89 | $86.47 | +2.93% | 1 | Jul 29, 2025 | |
| MRK Merck & Co. | Downgraded: Hold | n/a | $118.72 | n/a | 3 | Nov 11, 2024 | |
| JNJ Johnson & Johnson | Downgraded: Hold | $150 | $225.33 | n/a | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $252 → $320 | $336.79 | n/a | 3 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $210 | $447.54 | n/a | 1 | Jun 11, 2021 |
Illumina
May 14, 2026
Upgraded: Buy
Price Target: $94 → $155
Current: $162.96
Upside: -4.88%
Abbott Laboratories
Apr 21, 2026
Downgraded: Hold
Price Target: $92
Current: $85.60
Upside: +7.48%
Pfizer
Feb 12, 2026
Downgraded: Hold
Price Target: $34 → $27
Current: $26.18
Upside: +3.13%
Eli Lilly and Company
Dec 16, 2025
Upgraded: Buy
Price Target: $700 → $1,230
Current: $1,105.00
Upside: +11.31%
Gilead Sciences
Aug 18, 2025
Upgraded: Buy
Price Target: $128
Current: $134.43
Upside: -4.78%
AbbVie
Aug 7, 2025
Upgraded: Buy
Price Target: $180 → $214
Current: $217.72
Upside: -1.71%
Bristol-Myers Squibb Company
Aug 5, 2025
Downgraded: Hold
Price Target: $65 → $42
Current: $57.18
Upside: -26.55%
Edwards Lifesciences
Jul 29, 2025
Upgraded: Buy
Price Target: $89
Current: $86.47
Upside: +2.93%
Merck & Co.
Nov 11, 2024
Downgraded: Hold
Price Target: n/a
Current: $118.72
Upside: n/a
Johnson & Johnson
Jul 23, 2024
Downgraded: Hold
Price Target: $150
Current: $225.33
Upside: n/a
Dec 21, 2023
Upgraded: Buy
Price Target: $252 → $320
Current: $336.79
Upside: n/a
Jun 11, 2021
Downgraded: Hold
Price Target: $210
Current: $447.54
Upside: n/a